SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) have signed a memorandum of understanding (MoU) that will set in motion plans for the entities to combine their respective expertise to create a precision medicine hub to advance cancer treatment.
By combining MSK’s clinical data and expertise with Sophia’s artificial intelligence (AI) platform, the pair-up is expected to unlock a new approach to multimodal precision oncology, the entities stated.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
While the specifics surrounding the proposed initiative have not yet been finalised, the entities said that for patients, the precision medicine hub will act as an incubation studio for the “discoveries of tomorrow”, equipped with a deployment platform to quickly deliver new capabilities to patients worldwide.
The hub is also envisioned as a way to move new discoveries from bench to clinical care faster than traditional models, with this protocol mooted to expand access to MSK’s oncology intelligence for patients globally.
Meanwhile, for biopharma partners, MSK and Sophia said the hub could provide dedicated infrastructure for next-generation companion diagnostics, clinical algorithm development, and evidence generation.
Ross Muken, president of Sophia Genetics, said: “Our work with MSK has always been about extending the reach of MSK’s clinical intelligence, and this joint venture is the most ambitious expression of that mission yet.
“Over the past several years, we’ve built SOPHiA DDM into a foundational AI and analytics layer for precision medicine, helping institutions across the world unlock the value of their clinical data. By combining MSK’s clinical leadership and deep clinical data with Sophia Genetics’ AI platform and global infrastructure, the precision medicine hub that we are discussing will help move precision oncology into the multimodal era and bring the benefits of MSK’s precision oncology to patients regardless of where they’re treated.”
Sophia and MSK have undertaken several collaborations in the past through previous licence agreements involving MSK assays such as MSK-IMPACT and MSK-ACCESS, while Sophia has brought MSK diagnostics to hospitals, labs, and patients in 35 countries via its SOPHiA data-driven medicine (DDM) platform.
Commenting on the MoU, Michael Frank, director of digital health business development at MSK, said: “This collaboration represents the future of applied precision oncology – where clinical expertise meets cutting-edge AI and robotics with the potential to transform cancer care at scale. By combining MSK’s deep clinical assets with Sophia Genetics’ powerful digital platform, we’re seeking to create a new paradigm to deliver personalised insights to patients.”
